MedTrace Logo

The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension

NCT01062763 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2014-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.

Conditions

  • Arterial Hypertension
  • Hypertension, Resistant to Conventional Therapy
  • Diabetes Mellitus

Interventions

DRUG

spironolactone

25 to 50 mg once daily

DRUG

placebo

addition of placebo 1 to 2 tablets daily

Sponsors & Collaborators

  • Ib Abildgaard Jacobsen

    lead OTHER

Principal Investigators

  • Ib A Jacobsen, DMSc · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-03-31
Completion
2012-05-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062763 on ClinicalTrials.gov